Table 3.
Overall survival (OS) and relapse-free survival (RFS) rates of HAL patients
| Overall survival rate | Relapse-free survival rate | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| 1-year | 3-year | 5-year | Median (year) | χ2, P | 1-year | 3-year | 5-year | Median (year) | χ2, P | |
| Sex | χ2 = 1.190, P = 0.275 | χ2 = 1.301, P = 0.254 | ||||||||
| Male (N = 86) | 37% | 30% | 15% | 1.53 | 54% | 54% | 54% | 7.00 | ||
| Female(N = 8) | 63% | 63% | 38% | 4.50 | 85% | 85% | / | 4.82 | ||
| AJCC 8th Edition stages* | χ2 = 3.640, P = 0.056 | χ2 = 1.526, P = 0.217 | ||||||||
| Early (N = 16) | 70% | 70% | 70% | 7.00 | 76% | 76% | 76% | 7.00 | ||
| Advanced (N = 54) | 32% | 26% | 15% | 1.45 | 47% | 47% | / | 1.86 | ||
| Pathomorphological classification** | χ2 = 0.010, P = 0.920 | χ2 = 1.141, P = 0.286 | ||||||||
| Typical (N = 27) | 36% | 36% | / | 1.50 | 35% | 35% | / | 1.62 | ||
| Atypical (N = 38) | 42% | 28% | 28% | 1.67 | 60% | 60% | 60% | 7.00 | ||
| Pathological differentiation*** | χ2 = 1.353, P = 0.508 | χ2 = 2.236, P = 0.327 | ||||||||
| Well-differentiated (N = 5) | 56% | / | / | 2.00 | 100% | / | / | 2.00 | ||
| Moderately-differentiated (N = 7) | 49% | 49% | 0% | 1.97 | 78% | / | / | 1.00 | ||
| Poorly-differentiated (N = 36) | 28% | 28% | / | 1.30 | 41% | 41% | / | 1.80 | ||
| Therapeutic methods**** | χ2 = 35.027, P<0.001 | χ2 = 5.613, P = 0.060 | ||||||||
| Surg (N = 49) | 53% | 53% | 36% | 5.18 | 66% | 66% | 40% | 4.61 | ||
| Chemo (N = 30) | 30% | 18% | / | 1.00 | 51% | 51% | / | 4.00 | ||
| Others (N = 8) | 0% | / | / | 0.75 | 0% | / | / | 1.38 | ||
| Total (N = 94) | 40% | 35% | 19% | 1.59 | 58% | 58% | 39% | 4.41 | ||
*
26 patients with unclear AJCC 8th Edition stage;
**
29 cases with unclear pathomorphological classification;
***
45 cases with unclear pathological differentiation;
****
7 patients with unclear therapeutic method.
Chemo, chemotherapy-based strategy; Surg, surgery-based strategy.